Determination of global DNA methylation level by methylation-sensitive comet assay in patients with urinary bladder cancer
Mutagenesis · 02.11.2024 · 39 (6) · 280-286
DOI: 10.1093/mutage/geae018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mutagenesis, online erschienen am 10.08.2024. Verfasst von Ozer Kocak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, DNA Methylation, Comet Assay. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Scientific Research Projects Unit (BAP) of Istanbul University-Cerrahpasa.
Abstract (Originalsprache)
DNA methylation is an important mechanism in the regulation of gene expression and maintenance of genomic integrity. Aberrant DNA methylation is an early event in carcinogenesis. DNA methyltransferase inhibitors are used to restore aberrant DNA methylation and inhibit tumor growth. Evaluation of DNA methylation level is important for an effective anti-cancer therapy. In the present study, the determination of global DNA methylation levels in patients with urinary bladder cancer was proposed. The methylation-sensitive comet assay determined the global DNA methylation level at the level of single cells. McrBC enzyme, a methylation-sensitive restriction endonuclease, was used for enzymatic digestion to generate additional breaks at methylated sites. % DNA methylation level was significantly higher in patients with bladder cancer compared to the control group. The clinical performance of % DNA methylation analysis by methylation-sensitive comet assay was evaluated by ROC curve. Using the cutoff value of 6.5% DNA methylation, 92% sensitivity, and 42% specificity were obtained. In conclusion, global DNA methylation measured by methylation-sensitive comet assay may be a promising noninvasive biomarker that reduces interventional tests required in the diagnosis and follow-up of urinary bladder cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biochemistry, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey.
- Department of Medical Biochemistry, T.C. Istanbul Yeniyuzyil University, Faculty of Medicine, Istanbul 34010Turkey.
- Department of Urology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul 34098,Turkey.
Förderung
- Scientific Research Projects Unit (BAP) of Istanbul University-Cerrahpasa
Zitieren
APA
Kocak, O., Kankaya, S., Kalender, G., Citgez, S., Onal, B., & Dincer, Y. (2024). Determination of global DNA methylation level by methylation-sensitive comet assay in patients with urinary bladder cancer. Mutagenesis, 39(6), 280-286. https://doi.org/10.1093/mutage/geae018
Vancouver
Kocak O, Kankaya S, Kalender G, Citgez S, Onal B, Dincer Y. Determination of global DNA methylation level by methylation-sensitive comet assay in patients with urinary bladder cancer. Mutagenesis. 2024;39(6):280-286. doi:10.1093/mutage/geae018
BibTeX
@article{Kocak2024,
author = {Kocak, Ozer and Kankaya, Selin and Kalender, Goktug and Citgez, Sinharib and Onal, Bulent and Dincer, Yildiz},
title = {Determination of global DNA methylation level by methylation-sensitive comet assay in patients with urinary bladder cancer},
journal = {Mutagenesis},
year = {2024},
volume = {39},
number = {6},
pages = {280--286},
doi = {10.1093/mutage/geae018}
}
EUVIMED